Halozyme Therapeutics, Inc. (HALO) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $69.50 -1.74%
EPS Growth %: +17.5%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: +17.5%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q1 loss of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.5 million versus the consensus estimate of $5.19 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q2 EPS by 1c
- SailPoint Technologies Holdings (SAIL) Tops Q2 EPS by 1c, Offers Guidance
- Hooker Furniture (HOFT) Tops Q1 EPS by 14c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
